Testing for HIV Integrase Inhibitor Resistance: 2024 and Beyond


Tuesday, July 30
Time: 7:00 - 8:30 a.m.
Location:McCormick Center MR#N231
Sponsored by Thermo Fisher Scientific


HIV drug Resistance (HIVDR) can emerge with use of antiretroviral (ARV) drug for HIV treatment and prevention. The increasing prevalence of drug-resistant HIV strains poses a serious threat to the progress made over the past decades in combating the HIV epidemic and can be attributed to various factors, including incomplete adherence to ARV drugs regimens, suboptimal drug availability, and transmission of drug-resistant HIV strains. The World Health Organization (WHO) estimates that approximately 10% of people initiating ARV treatment (ART) globally have drug resistant HIV strains. This workshop will bring forward the perspectives of key option leaders in the field of HIVDR to discuss the current state of drug resistance globally, use of HIV drug resistance testing for public health surveillance and clinical management of person living with HIV (PLWH), and new challenges related to detection and monitoring HIVDR.


Olga Baran
Senior Manager, Global Market Development, qPCR Molecular Diagnostics, Thermo Fisher Scientific


Michael Jordan, M.D.
Associate Professor, Tufts University

Susan Eshleman, M.D., Ph.D.
Directory, HIV Prevention Trials Network (HPTN) Laboratory Center, Professor of Pathology, Johns Hopkins University, Johns Hopkins Bayview Medical Center

Conference registration is now open

Check out the scientific sessions at ADLM 2024.  Register and start planning your schedule today.

Explore the conference program

ADLM 2024 offers something for everyone in laboratory medicine, from Plenaries featuring world-renowned scientists to intimate Roundtables.